Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Climb Bio

Request full access

Rethinking treatment for nervous system disorders, empowering patients to live on their own terms

Wellesley, United StatesFounded 2018Biotech & Life Sciences

About Climb Bio

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Seattle and Cambridge, United Kingdom. The company is dedicated to developing innovative therapies for chronic pain and neuropsychiatric conditions. Eliem operates in the life sciences sector, primarily targeting patients who suffer from debilitating conditions that lack effective treatment options. The company's business model revolves around extensive research and development (R&D) to create novel pharmaceutical solutions. Eliem generates revenue through partnerships, licensing agreements, and potential future sales of its proprietary drugs. The company recently announced an agreement to acquire Tenet Medicines, Inc., and a concurrent $120 million private placement of common stock with a syndicate of institutional life science investors. This acquisition aims to advance TNT119, an anti-CD19 antibody designed for treating a broad range of autoimmune diseases.

Source: Dealroom company data

At a glance

Status
Operational
Employees
41
Open positions
None listed
Dealroom signal
94.1/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Neurology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Investment activity
1 company, latest Apr 2024
Capital deployed
—
Preferred round
ACQUISITION

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
PRIVATE PLACEMENT NON VCOther financing Apr 2026 $110M — RA Capital Management · Driehaus Capital Management · Woodline Partners · Affinity Asset Advisors ↗
PRIVATE PLACEMENT VCOther financing Apr 2024 $120M — Janus Henderson Investors · Samsara BioCapital · Deep Track Capital · RA Capital Management ↗
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowthEBITDAMargin
2026 — —
2025 — —
2024 — —
2023 — —
2022 — —
2021 — —
2020 — —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Climb Bio website traffic

Latest recorded traffic for Climb Bio is 1.9K monthly website visits, up 72.7% over the last three months. Climb Bio's team grew 17.1% over the past year.

Latest monthly visits1.9K 3-month web change+72.7% 1-year team growth+17.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Climb Bio in the Wellesley ecosystem

Live from Dealroom

The Climb Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

20 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • RA Capital Management
  • Intermediate Capital Group
  • Access Biotechnology
  • LifeArc
  • Acorn Bioventures
  • Samlyn Capital

Other known investors14 additional known investors

  • ADAR1 Capital Management
  • Affinity Asset Advisors
  • Ally Bridge Group
  • Boxer Capital
  • Cormorant Asset Management
  • Deep Track Capital
  • Driehaus Capital Management
  • Great Point Partners
  • Janus Henderson Investors
  • Pontifax AgTech
  • Redmile Group
  • Samsara BioCapital
  • Sirenia Capital Management
  • Woodline Partners
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Wellesley HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Climb Bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Climb Bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.